Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Oncofertility & Fertility Preservation

Banking before chemotherapy, radiation, or gender-affirming care

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Guideline-endorsed clinical practice (ASCO, ASRM, AUA)

Reference only. Not medical advice.

What can go wrong

The principal risk is omission - failure to counsel or refer in time, especially for adolescents, the acutely ill, and transgender patients. For prepubertal boys, no proven option exists yet (testicular tissue banking is research-stage). Cancer itself (especially testicular cancer, lymphoma) can lower baseline sperm quality, so a single suboptimal pre-treatment sample may be the only window.

This is something to take to a clinician. The Atlas can tell you what is known about oncofertility & fertility preservation in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Oncofertility addresses fertility loss from gonadotoxic treatment - alkylating chemotherapy, testicular/pelvic radiation, bone-marrow transplant conditioning - and, increasingly, from gender-affirming hormone therapy. ASCO and ASRM recommend offering sperm cryopreservation to all post-pubertal males before such treatment, ideally before the first dose. The intervention is high-value and time-critical, yet referral rates remain imperfect, and prepubertal preservation is still experimental.

The most time-sensitive, highest-value reason to bank sperm.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Banking before chemotherapy/radiation/transplant
  • Fertility preservation before estrogen-based gender-affirming therapy
  • Counseling adolescents and young adults with cancer
  • Documenting baseline before testis surgery

How it works

Alkylating agents and radiation damage rapidly dividing spermatogonial stem cells, sometimes causing prolonged or permanent azoospermia; recovery is dose- and agent-dependent and unpredictable. Estrogen and antiandrogens suppress the HPG axis and spermatogenesis. Because damage can be irreversible and onset is fast, banking before the first treatment cycle captures the best-quality sample available.

What people get wrong

  • Often saidYou can always bank sperm after a couple chemo cycles

    ActuallyEven one cycle of gonadotoxic therapy can damage spermatogenesis; the recommendation is to bank before the first dose.

  • Often saidFertility always returns after chemo

    ActuallyRecovery depends on regimen and dose; some men remain permanently azoospermic, which is why pre-treatment banking matters.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

How we got here

The term 'oncofertility' was coined by Teresa Woodruff (~2006) to formalize the bridge between cancer treatment and reproductive medicine. ASCO's fertility-preservation guidelines and oncofertility consortia institutionalized pre-treatment counseling, while gender-affirming-care fertility preservation emerged more recently as a parallel priority.

  1. 2006Oncofertility framework articulated; first ASCO fertility-preservation guideline
  2. 2013/2018ASCO guideline updates reinforce referral
  3. 2010s-2020sFertility preservation extended to transgender patients before hormone therapy

Set against the alternatives

Versus elective consumer banking, oncofertility has a clear, guideline-backed indication and urgency. The limiting step is systems-level: timely counseling and access, not the cryopreservation technology itself.

What we do not know

  • How can referral rates and timeliness be improved, especially for adolescents and transgender patients?
  • Will testicular-tissue cryopreservation and in-vitro maturation become clinically viable for prepubertal boys?
  • How should preservation be funded so cost does not determine who gets the option?

At a glance

Core recommendation
Offer banking before gonadotoxic therapy (ASCO)
Highest-risk agents
alkylators (cyclophosphamide), procarbazine, testicular irradiation
Prepubertal option
testicular tissue cryopreservation - still experimental
Gender-affirming care
estrogen/antiandrogens can impair spermatogenesis; bank before starting

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Oncofertility & Fertility Preservation. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • ASCO Fertility Preservation Guideline2006/2013/2018

    Recommends clinicians offer and refer for sperm banking before gonadotoxic therapy

  • Survivorship studies of post-chemo azoospermiavarious

    Alkylating-agent and testicular-radiation regimens associated with high rates of prolonged azoospermia; recovery variable

  • Fertility outcomes in transgender women on estrogen2010s-2020s

    Estrogen/antiandrogen therapy impairs spermatogenesis, supporting preservation before initiation